Core Points - The chairman and president of Beijing University Pharmaceutical, Xu Xiren, has been criminally detained and is currently cooperating with investigations, temporarily unable to perform his duties [1][2] - The company has stated that its control has not changed, and the board of directors is operating normally, with financial and operational management remaining stable [2] - Xu Xiren remains the actual controller of the company, having authorized other executives to perform his duties during his absence [2] Company Background - Xu Xiren has been in control of Beijing University Pharmaceutical for only three months, having acquired control through a transaction involving the purchase of 100% of Southwest Synthetic Pharmaceutical Group [3] - The company has a long history, originally established in 1965, and has undergone several ownership changes, including being part of the Ping An Group and later transitioning to Xu Xiren's control in late 2024 [4] - The company reported a revenue of 957 million yuan for the first half of 2025, a decrease of 5.04% year-on-year, while net profit increased by 15.51% to 100 million yuan [4] Market Performance - As of October 29, the stock price of Beijing University Pharmaceutical closed at 6.17 yuan per share, with a total market capitalization of 3.677 billion yuan [5]

Core Points - The chairman and president of Beijing University Pharmaceutical, Xu Xiren, has been criminally detained and is temporarily unable to perform his duties [1] - The company has stated that its control has not changed and that its board of directors is operating normally [2] - Xu Xiren remains the actual controller of the company despite his detention [2] Company Control and Management - The company has made arrangements for its operations, with Xu Xiren authorizing other executives to perform his duties during his absence [2] - Xu Xiren acquired control of Beijing University Pharmaceutical through a transaction in December 2024, purchasing the controlling stake for 1 yuan while assuming significant debts [3] - Xu Xiren has held the positions of actual controller, chairman, and president of the company since his appointment in July 2025 [4] Financial Performance - In the first half of 2025, the company reported revenues of 957 million yuan, a year-on-year decrease of 5.04%, while net profit attributable to shareholders reached 100 million yuan, an increase of 15.51% [4] - The termination of a long-term service contract with Peking University International Hospital in April 2025 is expected to reduce the company's sales revenue and net profit in the second half of 2025 [4] Market Reaction - As of October 29, the company's stock price closed at 6.17 yuan per share, with a total market capitalization of 3.677 billion yuan [5]

Core Viewpoint - The chairman and president of Beijing University Pharmaceutical (北大医药), Xu Xiren, has been criminally detained, affecting his ability to perform his duties, while the company's control and operations remain stable [2][6]. Group 1: Management Changes - Xu Xiren has temporarily delegated his responsibilities to board member Chen Yuezhong and executive vice president Yu Mengchuan due to personal reasons [5]. - The delegation of authority is effective from the date of the written authorization and will remain in effect until Xu Xiren provides written notice to terminate it [5]. Group 2: Company Operations - As of the announcement date, the company has stated that its control has not changed, the board is functioning normally, and its financial and operational management is stable [2][6]. - The company is currently unaware of the progress or conclusions of the investigation into Xu Xiren's detention [6]. Group 3: Financial Impact - Following Xu Xiren's leadership, the company has faced challenges, including the termination of a long-term service contract with Beijing University International Hospital, which is expected to reduce sales revenue by approximately 600 million yuan and net profit by about 40 million yuan in 2025 [7]. - The company anticipates a revenue decrease of approximately 1.027 billion yuan starting in 2026, which is about 49.85% of the 2024 revenue [7].

Core Viewpoint - The chairman and president of Beijing University Pharmaceutical, Xu Xiren, has been criminally detained, affecting his ability to perform duties, while the company has appointed other executives to take over his responsibilities [1][4]. Group 1: Company Announcement - On October 25, the company announced that Xu Xiren temporarily could not perform his duties due to personal reasons and authorized Chen Yuezhong to act as chairman and Yu Mengchuan as president [4]. - The authorization is effective from the date of signing until Xu Xiren provides written notice to terminate it [4]. - The company has assured that its governance structure and internal control mechanisms are intact, and operations remain normal despite the leadership change [4]. Group 2: Company Background - Beijing University Pharmaceutical was established in 1965 and listed on the Shenzhen Stock Exchange in 1997 [5]. - The company became a member of the Ping An Group in 2022 and is controlled by Xu Xiren [5]. - The company focuses on drug research, production, and sales, with a portfolio of 166 drug approvals and 13 first-generic drug approvals [5]. Group 3: Financial Performance - In the first half of the year, the company reported total revenue of 957 million yuan, a decrease of 5.04% year-on-year, while net profit increased by 15.51% to 100 million yuan [6].

Core Points - The chairman and president of Beijing University Pharmaceutical, Xu Xiren, has been criminally detained and is cooperating with investigations, temporarily unable to perform his duties [1][3] - The company has appointed Chen Yuezhong as acting chairman and Yu Mengchuan as acting president and legal representative during this period [3] - The company assures that there has been no change in control, and the board is operating normally with financial and operational management unaffected [3] Company Overview - Beijing University Pharmaceutical, established in 1965, primarily engages in the research, production, and sales of chemical drug formulations, as well as pharmaceutical distribution and medical services [3] - The company’s product range includes anti-infection, analgesic, psychiatric, digestive system, and cardiovascular drugs [3] - The distribution business operates through wholly-owned subsidiaries, focusing on third-party drug distribution, retail, hospital procurement, and pharmacy management [3] Financial Performance - In the first half of the year, the company reported total revenue of 957 million yuan, a decrease of 5.04% year-on-year, while net profit increased by 15.51% to 100 million yuan [6] - As of October 29, the company's stock price fell by 0.16%, with a total market capitalization of approximately 3.7 billion yuan [6]

Core Viewpoint - Deng Xiaofeng, a well-known private equity fund manager at Gao Yi Asset, has made significant adjustments to his portfolio in the third quarter, notably increasing his stake in Beixin Building Materials while taking profits from other holdings like Zijin Mining and Yun Aluminum [1][10]. Group 1: Investment Actions - Deng Xiaofeng's Gao Yi Xiaofeng No. 2 Fund and Foreign Trade Trust - Gao Yi Xiaofeng Hongyuan Trust Plan entered the top ten circulating shareholders of Beixin Building Materials, holding 12.865 million shares and 11.948 million shares respectively, with a total market value of 533 million yuan [3][4]. - In the same period, the Gao Yi Xiaofeng No. 2 Fund reduced its holdings in Zijin Mining by 18.6 million shares, while the Foreign Trade Trust plan exited the top ten shareholders of Zijin Mining [10]. - The Gao Yi Xiaofeng No. 2 Fund and Foreign Trade Trust plan also reduced their stakes in Yun Aluminum by 4.8 million shares and 2.3 million shares respectively [10]. Group 2: Company Performance - Beixin Building Materials reported a revenue of 6.347 billion yuan for the third quarter, a decrease of 6.2% year-on-year, and a net profit attributable to shareholders of 656.8 million yuan, down 29.47% year-on-year [7][8]. - The company's stock price has declined over 20% year-to-date, reflecting ongoing market challenges [5]. - Despite the downturn, Beixin's waterproof and coating businesses are expanding, indicating potential for future growth [8]. Group 3: Market Trends - Many private equity firms are optimizing their portfolios in the third quarter, focusing on a balanced allocation across technology, cyclical, and dividend sectors [1][12]. - The market has seen rapid rotation, with structural overvaluation becoming a concern, prompting firms to adjust their holdings accordingly [13][14].

Core Viewpoint - The incident at Chengxing Chemical was initially reported as an explosion but was later clarified to be a fire, with no casualties and an ongoing investigation into the cause [1][2]. Company Overview - Chengxing Co., Ltd. is a leading domestic phosphorus chemical enterprise, primarily engaged in the production of yellow phosphorus, phosphoric acid, and phosphate products [1]. - The company has phosphorus mining resources in Yunnan, ensuring its production needs [1]. Financial Performance - In the first half of 2025, Chengxing's revenue increased by 9.85% to 1.776 billion yuan, and the net profit attributable to shareholders rose by 211.08% to 18.56 million yuan, marking a turnaround from losses [2]. - The main products, yellow phosphorus and phosphoric acid, contributed significantly to the revenue, with yellow phosphorus production capacity at 160,000 tons per year, ranking among the top in the country [2]. Incident Details - The fire was caused by a yellow phosphorus tank truck leak, which ignited upon contact with air, but was fully extinguished without any injuries reported [2]. - The affected plant is scheduled for relocation, and the incident is not expected to have a significant impact on production [2]. Future Plans - Chengxing is planning to relocate its Jiangyin plant to the Jiangyin Lingang Chemical Park, where it will implement advanced production processes and equipment to enhance product competitiveness [2]. - The project has received the necessary investment project filing certificate and has initiated various assessments [2]. Stock Market Reaction - Following the incident, Chengxing's stock price experienced a decline, closing at 9.80 yuan per share, down 4.48% [3]. Ownership Changes - In 2022, the controlling shareholder of Chengxing changed from Chengxing Group to Wuxi Xingshengzhou Technology Partnership, with Li Xingxing becoming the new actual controller [3]. - Li Xingxing is the son of Li Shufu, chairman of Geely Holding Group, and has been involved in various business ventures with his father [3].

Group 1 - The stock of Chengxing Co., Ltd. experienced a significant drop, hitting the daily limit down after a previous streak of gains, with a trading volume exceeding 1.2 billion yuan [1][3] - Prior to the drop, the stock had achieved limit-up gains for four consecutive trading days and reached a nearly two-year high during intraday trading [3] Group 2 - The stock price fluctuations included a "Tian Di Ban" phenomenon, indicating extreme volatility in the market [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: Regal Hotels International Holdings Limited (富豪酒店國際控股有限公司) (於百慕達註冊成立之有限公司) 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00078 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | HKD | | 0.1 HKD | | 200,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 2,000,000 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本聯合公佈之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不對因本聯合公佈全部或任何部份內容而產生或因倚賴該等內容 而引致之任何損失承擔任何責任。 （股份代號: 78） RH International Finance Limited (Incorporated in the British Virgin Islands with limited liability) （股份代號: 5425） 聯合公佈 有 關 延 後 永續證券之分派 及 未 付 分 派 1 於本聯合公佈刊發日期，富豪之董事會包括下列成員： 茲提述由 Regal Hotels International Holdings Limited（「富豪」）及 RH International Finance Limited（「RH International」）刊發日期為二零二五年三月二十八日之聯合公佈，內容 有關225,000,000美元6.50%擔保優先永續證券（「永續證券」）之延後分派。 RH International 乃為永續證券之發行人，宣佈根據永續證券條件 4(e)，其 ...